The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform


Argos in The News

Dr. Lee F. Allen Joins Argos Therapeutics as Chief Medical Officer
Read more

Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis
Read more

Argos Therapeutics to Participate in the ROTH Immuno-Oncology Corporate Access Day
Read more

> More News & Events >>>


When Our Company Was Founded


First Arcelis product (AGS-003) clinical trial initiated in mRCC


Phase 3 mRCC ADAPT Study Launched


Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC